NYSEAMERICAN:VNRXVolitionRX Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding VolitionRX Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $3.46 +0.11 (+3.28 %) (As of 08/14/2020 04:00 PM ET) Add Compare Share Today's Range$3.27Now: $3.46▼$3.5050-Day Range N/A52-Week Range$2.22Now: $3.46▼$6.84Volume297,093 shsAverage Volume348,347 shsMarket Capitalization$142.57 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAnalyst RatingsChartCompetitorsEarningsInsider TradesInstitutional OwnershipHeadlinesShort InterestSocial Media VolitionRX Limited, a life sciences company, engages in the development of blood tests to help diagnose a range of cancers and other diseases worldwide. The company develops blood-based Nu.Q immunoassays to detect specific biomarkers. VolitionRX Limited is based in Singapore.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingVolitionRX has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $8.33, VolitionRX has a potential upside of 140.8% from its current price of $3.46.Amount of Analyst CoverageVolitionRX has only been the subject of 1 research reports in the past 90 days. Previous Next 2.6 Community Rank Outperform VotesVolitionRX has received 183 “outperform” votes. (Add your “outperform” vote.)Underperform VotesVolitionRX has received 166 “underperform” votes. (Add your “underperform” vote.)Community SentimentVolitionRX has received 52.44% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about VolitionRX and other stocks. Vote “Outperform” if you believe VNRX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe VNRX will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldVolitionRX does not currently pay a dividend.Dividend GrowthVolitionRX does not have a long track record of dividend growth. Previous Next 3.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, VolitionRX insiders have bought more of their company's stock than they have sold. Specifically, they have bought $12,000.00 in company stock and sold $0.00 in company stock. Previous Next 0.0 Earnings and Valuation Previous Next Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.82 out of 5 stars Industry, Sector and Symbol Stock Exchange NYSEAMERICAN Industry Medical Laboratories & Research Sub-IndustryN/A SectorMedical Current SymbolNYSEAMERICAN:VNRX Previous SymbolNYSEMKT:VNRX CUSIPN/A CIKN/A Webwww.volitionrx.com Phone646 650 1351Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees44 Outstanding Shares41,205,000Market Cap$142.57 million Next Earnings Date11/10/2020 (Estimated) OptionableNot Optionable $3.46 +0.11 (+3.28 %) (As of 08/14/2020 04:00 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive VNRX News and Ratings via Email Sign-up to receive the latest news and ratings for VNRX and its competitors with MarketBeat's FREE daily newsletter. VolitionRX (NYSEAMERICAN:VNRX) Frequently Asked Questions Do Wall Street analysts recommend investors buy shares of VolitionRX? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for VolitionRX in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for VolitionRX. When is VolitionRX's next earnings date? VolitionRX is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020. View our earnings forecast for VolitionRX. How were VolitionRX's earnings last quarter? VolitionRX Ltd (NYSEAMERICAN:VNRX) announced its quarterly earnings results on Thursday, May, 7th. The medical research company reported ($0.14) earnings per share for the quarter, missing analysts' consensus estimates of ($0.10) by $0.04. The medical research company earned $0.54 million during the quarter. View VolitionRX's earnings history. What price target have analysts set for VNRX? 3 equities research analysts have issued 12 month price targets for VolitionRX's shares. Their forecasts range from $7.00 to $10.00. On average, they expect VolitionRX's share price to reach $8.33 in the next year. This suggests a possible upside of 140.8% from the stock's current price. View analysts' price targets for VolitionRX. Has VolitionRX been receiving favorable news coverage? Headlines about VNRX stock have trended negative this week, InfoTrie reports. The research firm identifies positive and negative press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. VolitionRX earned a daily sentiment score of -2.7 on InfoTrie's scale. They also assigned news stories about the medical research company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the next several days. View the latest news about VolitionRX. Are investors shorting VolitionRX? VolitionRX saw a increase in short interest during the month of June. As of June 15th, there was short interest totaling 544,700 shares, an increase of 26.3% from the May 31st total of 431,200 shares. Based on an average daily trading volume, of 299,600 shares, the short-interest ratio is presently 1.8 days. Approximately 2.0% of the company's shares are short sold. View VolitionRX's Short Interest. Who are some of VolitionRX's key competitors? Some companies that are related to VolitionRX include Spectral Medical (EDT), ANGLE (AGL), Proteome Sciences (PRM), DiaSorin (DIA) and Premaitha Health (NIPT). View all competitors. What other stocks do shareholders of VolitionRX own? Based on aggregate information from My MarketBeat watchlists, some companies that other VolitionRX investors own include Chesapeake Energy (CHKAQ), Chesapeake Energy (CHKAQ), Bausch Health Companies (BHC), Verastem (VSTM), Bausch Health Companies (BHC), Protalix Biotherapeutics (PLX), Ring Energy (REI), Ring Energy (REI), Clovis Oncology (CLVS) and Crispr Therapeutics (CRSP). Who are VolitionRX's key executives? VolitionRX's management team includes the following people: Dr. Martin Charles Faulkes, Exec. Chairman (Age 75)Mr. Cameron Reynolds, Founder, CEO, Pres & Director (Age 48)Dr. Jacob Vincent Micallef Ph.D., MBA, Chief Scientific Officer (Age 63)Dr. Jason Bradley Terrell, Chief Medical Officer (Age 39)Mr. Rodney Gerard Rootsaert LLB, Corp. Sec. (Age 48) What is VolitionRX's stock symbol? VolitionRX trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "VNRX." Who are VolitionRX's major shareholders? VolitionRX's stock is owned by many different retail and institutional investors. Top institutional shareholders include Bank of New York Mellon Corp (0.19%), Goldman Sachs Group Inc. (0.14%), Ovata Capital Management Ltd (0.12%), Advisor Group Holdings Inc. (0.10%), New York State Common Retirement Fund (0.06%) and Bank of America Corp DE (0.06%). Company insiders that own VolitionRX stock include Cameron John Reynolds, Corp Ltd Eight, Guy Archibald Innes and Martin Charles Faulkes. View institutional ownership trends for VolitionRX. Which major investors are selling VolitionRX stock? VNRX stock was sold by a variety of institutional investors in the last quarter, including Advisor Group Holdings Inc., and Bank of America Corp DE. View insider buying and selling activity for VolitionRX. Which major investors are buying VolitionRX stock? VNRX stock was purchased by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, Ovata Capital Management Ltd, New York State Common Retirement Fund, American International Group Inc., UBS Group AG, and Goldman Sachs Group Inc.. Company insiders that have bought VolitionRX stock in the last two years include Cameron John Reynolds, Corp Ltd Eight, Guy Archibald Innes, and Martin Charles Faulkes. View insider buying and selling activity for VolitionRX. How do I buy shares of VolitionRX? Shares of VNRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is VolitionRX's stock price today? One share of VNRX stock can currently be purchased for approximately $3.46. How big of a company is VolitionRX? VolitionRX has a market capitalization of $142.57 million. VolitionRX employs 44 workers across the globe. What is VolitionRX's official website? The official website for VolitionRX is www.volitionrx.com. How can I contact VolitionRX? The medical research company can be reached via phone at 646 650 1351. This page was last updated on 8/15/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
